Navigation Links
Reportlinker Adds Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Date:6/1/2011

NEW YORK, June 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017

http://www.reportlinker.com/p0546768/Myelodysplastic-Syndrome-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, "Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global myelodysplastic syndrome (MDS) therapeutic market. The report identifies the key trends shaping and driving the global MDS therapeutic market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global MDS therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global myelodysplastic syndrome (MDS) market was valued at $652.6m in 2010 and forecasts it to grow at a Compound Annual Growth Rate (CAGR) of 12.2% to reach $1.5 billion by 2017. This growth forecast is primarily attributed to the currently approved drugs reaching their peak sales during the forecast period and secondarily due to a strong pipeline. The existing market is strong although with high unmet need. The market is represented by three approved drugs Vidaza (azacitidine), Dacogen (decitabine) and Revlimid (lenalidomide).

Scope

The report provides information on the key drivers and challenges of the MDS therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) MDS therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as HDCA (Histone deacetylase inhibitors) inhibitors, anti–CD33 mAb (monoclonal antibody) and VEGF (vascular endothelial growth receptor) inhibitors.

- Analysis of the current and future competition in the seven key countries MDS therapeutics market. Key market players covered are Amgen Inc, Arno Therapeutics, Array Biopharma, Cyclacel Pharmaceuticals Inc, Medac GmbH, Novartis AG, Onconova Therapeutics, Sanofi-Aventis, Synta Pharmaceuticals, S* BIO Pte, Telik Inc.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the MDS therapeutics market.

- Analysis of key recent licensing and partnership agreements in Myelodysplastic Syndrome Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global MDS therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global MDS therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global MDS therapeutics market landscape? – Identify, understand and capitalize.

1 Table of contents

1 Table of contents 2

1.1 List of Tables 4

1.2 List of Figures 5

2 Introduction 6

2.1 Overview 6

2.2 Epidemiology 8

2.3 Etiology and Pathophysiology 9

2.4 Signs and Symptoms 9

2.5 Diagnosis 9

2.6 Treatment 10

2.7 GlobalData Pipeline Report Guidance 11

3 Myelodysplastic Syndrome: Market Characterization 12

3.1 Major Markets, Market Size (2005-2010) 12

3.2 Major Markets, Market Forecast (2010-2017) 14

3.3 US Market Size (2005-2010) 16

3.4 US Market Forecast (2010-2017) 17

3.5 France Market Size (2005-2010) 18

3.6 France Market Forecast (2010-2017) 19

3.7 Germany Market Size (2005-2010) 20

3.8 Germany Market Forecast (2010-2017) 21

3.9 Italy Market Size (2005-2010) 22

3.10 Italy Market Forecast (2010-2017) 23

3.11 Spain Market Size (2005-2010) 24

3.12 Spain Market Forecast (2010-2017) 25

3.13 UK Market Size (2005-2010) 26

3.14 UK Market Forecast (2010-2017) 27

3.15 Japan Market Size (2005-2010) 28

3.16 Japan Market Forecast (2010-2017) 29

3.17 Drivers and Barriers for Myelodysplastic Syndrome Therapeutic Market 30

3.17.1 Drivers for Myelodysplastic Syndrome Market 30

3.17.2 Barriers for Myelodysplastic Syndrome Market 30

3.18 Opportunity and Unmet Need 31

3.19 Key Takeaway 32

4 Myelodysplastic Syndrome Market: Competitive Assessment 33

4.1 Overview 33

4.1.1 Strategic Competitor Assessment 33

4.2 Myelodysplastic Syndrome Market Marketed Products Profile 34

4.2.1 Vidaza (azacytidine) 34

4.2.2 Dacogen (decitabine) 35

4.2.3 Revlimid (lenalidomide) 37

4.3 Key Takeaway 37

5 Myelodysplastic Syndrome: Pipeline Assessment 38

5.1 Overview 38

5.2 Strategic Pipeline Assessment 38

5.3 Myelodysplastic Syndrome Pipeline Analysis – Pipeline by Clinical Phases of Development 39

5.3.1 Myelodysplastic Syndrome Therapeutics – Phase III Clinical Pipeline 39

5.3.2 Myelodysplastic Therapeutics – Phase II Clinical Pipeline 40

5.3.3 Myelodysplastic Syndrome Therapeutics – Phase I Clinical Pipeline 41

5.3.4 Myelodysplastic Syndrome Therapeutics – Preclinical Pipeline 41

5.4 Myelodysplastic Syndrome Pipeline by Mechanism of Action 41

5.5 Myelodysplastic Syndrome Technology Trends Analytical Framework 43

5.6 Myelodysplastic Syndrome Clinical Pipeline by Monotherapy and Combination Therapy 44

5.7 Myelodysplastic Syndrome Therapeutics – Promising Drugs under Clinical Development 44

5.8 Molecule Profile for Promising Drugs under Clinical Development 45

5.8.1 Treosulfan 45

5.9 Key Takeaway 45

6 Myelodysplastic Syndrome Therapeutics – Clinical Trials Mapping 46

6.1 Clinical Trials Mapping by Region/Country 46

6.2 Clinical Trials Mapping by Phase 47

6.3 Clinical Trials Mapping by Trial Status 48

6.4 Clinical Trials Mapping by Prominent Sponsors 49

6.5 Participants in Therapeutic Clinical Trials - Companies 51

7 Myelodysplastic Syndrome Therapeutics: Strategic Assessment 52

7.1 Key Events Impacting the Future Market 52

7.2 Future Market Competition Scenario 53

8 Global Myelodysplastic Syndrome Therapeutics: Future Players in The Market 54

8.1 Introduction 54

8.2 Amgen Inc. 55

8.2.1 Company Overview 55

8.2.2 Financial Overview 55

8.2.3 Business Overview 56

8.3 Arno Therapeutics Inc. 59

8.3.1 Company Overview 59

8.3.2 Business Overview 59

8.4 Array Bippharma 60

8.4.1 Company Overview 60

8.5 Cyclacel Pharmaceuticals Inc. 62

8.5.1 Company Overview 62

8.6 Medac GmbH 63

8.6.1 Company Overview 63

8.7 Novartis AG 64

8.8 Onconova Therapeutics 69

8.8.1 Company Overview 69

8.9 Sanofi-Aventis 70

8.9.1 Company Overview 70

8.9.2 Financial Overview 70

8.9.3 Business Description 70

8.10 Synta Pharmaceuticals 74

8.10.1 Company Overview 74

8.10.2 Financial Overview 74

8.10.3 Business Overview 74

8.11 S* BIO Pte 76

8.11.1 Company Overview 76

8.12 Telik Inc. 77

8.12.1 Company Overview 77

8.12.2 Financial Overview 77

8.12.3 Business Overview 77

8.13 Other Companies in Pipeline – Tabular Presentation 78

9 Licensing and Partnership Deals 80

10 Global Myelodysplastic Syndrome Market: Appendix 81

10.1 Definitions 81

10.2 Acronyms 81

10.3 Research Methodology 83

10.3.1 Coverage 83

10.3.2 Secondary Research 83

10.3.3 Forecasting 84

10.3.4 Primary Research 86

10.3.5 Expert Panels 86

10.4 Contact Us 86

10.5 Disclaimer 86

10.6 Sources 87

1.1 List of Tables

Table 1: French-British-American Classification of MDS 6

Table 2: World Health Organisation Classification of MDS 7

Table 3: IPSS Point Chart for MDS 8

Table 4: IPSS Classification Chart for MDS 8

Table 5: MDS Therapeutics, Global, Market Revenue ($m), 2005-2010 12

Table 6: MDS Therapeutics, Global, Revenue Forecasts ($m), 2010-2017 14

Table 7: MDS Therapeutics, The US, Market Historical Revenue ($m), 2005-2010 16

Table 8: MDS Therapeutics, The US, Historical Revenue Forecasts ($m), 2010-2017 17

Table 9: MDS Therapeutics, France, Market Revenue ($m), 2005-2010 18

Table 10: MDS Therapeutics, France, Revenue Forecasts ($m), 2010-2017 19

Table 11: MDS Therapeutics, Germany, Market Revenue ($m), 2005-2010 20

Table 12: MDS Therapeutics, Germany, Revenue Forecasts ($m), 2010-2017 21

Table 13: MDS Therapeutics, Italy, Market Revenue ($m), 2005-2010 22

Table 14: MDS Therapeutics, Italy, Revenue Forecasts ($m), 2010-2017 23

Table 15: MDS Therapeutics, Spain, Market Revenue ($m), 2005-2010 24

Table 16: MDS Therapeutics, Spain, Revenue Forecasts ($m), 2010-2017 25

Table 17: MDS Therapeutics, The UK, Market Revenue ($m), 2005-2010 26

Table 18: MDS Therapeutics, The UK, Revenue Forecasts ($m), 2010-2017 27

Table 19: MDS Therapeutics, Japan, Market Revenue ($m), 2005-2010 28

Table 20: MDS Therapeutics, Japan, Revenue Forecasts ($m), 2010-2017 29

Table 21: MDS Therapeutics – Phase III Clinical Pipeline, 2011 39

Table 22: MDS Therapeutics – Phase II Clinical Pipeline, 2011 40

Table 23: MDS Therapeutics – Phase I Clinical Pipeline, 2011 41

Table 24: MDS Therapeutics – Preclinical Pipeline, 2011 41

Table 25: Mechanism of Action That Constitute the Others in the Above Pie Chart 42

Table 26: MDS Therapeutics – Promising Drugs Under Clinical Development, 2011 44

Table 27: MDS Clinical Trials by Region – Number, 2011 46

Table 28: MDS Clinical Trials by Phase and Country, 2011 47

Table 29: MDS Clinical Trials by Status and Country, 2011 48

Table 30: MDS Clinical Trials by Sponsors and Country, 2011 49

Table 31: MDS Clinical Trials by Prominent Sponsors, 2011 50

Table 32: Amgen – Promising Molecules in Pipeline for Oncology, 2011 55

Table 33: Amgen Inc, Deals 2009-2011 57

Table 34: Arno Therapeutics – Promising Molecules in Pipeline for Oncology, 2011 59

Table 35: Array Biopharma – Promising Molecules in Pipeline for Oncology, 2011 60

Table 36: Array Biopharma Deals, 2009-2011 61

Table 37: Cyclacel Pharma – Promising Molecules in Pipeline for Oncology, 2011 62

Table 38: Medac GmbH – Promising Molecules in Pipeline for Oncology, 2011 63

Table 39: Medac GmbH Deals, 2009-2011 63

Table 40: Novartis – Oncology Pipeline, 2010 65

Table 41: Novartis Deals, 2009-2010 66

Table 42: Onconova Therapeutics – Promising Molecules in Pipeline for Oncology, 2011 69

Table 43: Onconova Therapeutics Deals, 2009-2011 69

Table 44: Sanofi-Aventis – Promising Molecules in Pipeline for Oncology, 2011 71

Table 45: Sanofi-Aventis Key Deals, 2010-2011 72

Table 46: Synta Pharmaceuticals – Promising Molecules in Pipeline for Oncology, 2011 74

Table 47: Synta Pharmaceuticals Deals, 2009-2011 75

Table 48: S* BIO Pte – Promising Molecules in Pipeline for Oncology, 2011 76

Table 49: Telik – Promising Molecules in Pipeline for Oncology, 2011 77

Table 50: Other Companies that have Molecules for MDS in Pipeline 78

Table 51: MDS Therapeutics, Licensing and Partnership Deals 80

1.2 List of Figures

Figure 1: MDS Therapeutics, Global, Market Revenue ($m), 2005-2010 12

Figure 2: MDS Therapeutics, Market Share ($m, %), 2010 13

Figure 3: MDS Therapeutics, Global, Revenue Forecasts ($m), 2010-2017 14

Figure 4: MDS Therapeutics, Forecast Market Share ($m, %), 2017 15

Figure 5: MDS Therapeutics, The US, Market Revenue ($m), 2005-2010 16

Figure 6: MDS Therapeutics, The US, Revenue Forecasts ($m), 2010-2017 17

Figure 7: MDS Therapeutics, France, Market Revenue ($m), 2005-2010 18

Figure 8: MDS Therapeutics, France, Revenue Forecasts ($m), 2010-2017 19

Figure 9: MDS Therapeutics, Germany, Market Revenue ($m), 2005-2010 20

Figure 10: MDS Therapeutics, Germany, Revenue Forecasts ($m), 2010-2017 21

Figure 11: MDS Therapeutics, Italy, Market Revenue ($m), 2005-2010 22

Figure 12: MDS Therapeutics, Italy, Revenue Forecasts ($m), 2010-2017 23

Figure 13: MDS Therapeutics, Spain, Market Revenue ($m), 2005-2010 24

Figure 14: MDS Therapeutics, Spain, Revenue Forecasts ($m), 2010-2017 25

Figure 15: MDS Therapeutics, The UK, Market Revenue ($m), 2005-2010 26

Figure 16: MDS Therapeutics, The UK, Revenue Forecasts ($m), 2010-2017 27

Figure 17: MDS Therapeutics, Japan, Market Revenue ($m), 2005-2010 28

Figure 18: MDS Therapeutics, Japan, Revenue Forecasts ($m), 2010-2017 29

Figure 19: Opportunity and Unmet Need in the MDS Therapeutic Market 31

Figure 20: Strategic Competitor Assessment of Marketed Products for MDS, 2010 33

Figure 21: Pipeline Products by Phase of Clinical Development, 2011 38

Figure 22: MDS Therapeutics Pipeline by Phase of Clinical Development, 2011 39

Figure 23: MDS Market – Clinical Pipeline by Mechanism Of Action, 2011 41

Figure 24: Technology Trends Analytical Framework of The MDS Pipeline, 2011 43

Figure 25: Technology Trends Analytical Framework of The MDS Pipeline - Description, 2011 43

Figure 26: MDS pipeline by The Nature of Therapy, 2011 44

Figure 27: MDS Clinical Trials by Region, 2011 46

Figure 28: MDS Clinical Trials by Phase, 2011 47

Figure 29: MDS Clinical Trials by Status, 2011 48

Figure 30: MDS Clinical Trials by Sponsors, 2011 49

Figure 31: MDS Clinical Trials by Prominent Sponsors, 2011 50

Figure 32: MDS Therapeutic Clinical Trial - Company Sponsors by Phase, 2011 51

Figure 33: MDS Therapeutics, Key Events Impacting Future Market 52

Figure 34: MDS Therapeutics, Strategic Assessment, 2011 53

Figure 35: MDS Therapeutics, Clinical Pipeline by Company, 2011 54

Figure 36: GlobalData market Forecasting Model, 2011 85

Companies Mentioned

Amgen Inc.

Arno Therapeutics Inc.

Array Bippharma

Cyclacel Pharmaceuticals Inc.

Medac GmbH

Novartis AG

Onconova Therapeutics

Sanofi-Aventis

Synta Pharmaceuticals

S* BIO Pte

Telik Inc.

To order this report:

Pathology Industry: Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Interventional Neurology - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
2. Reportlinker Adds Chinas Guidebook for Pharmaceutical Patent Protection
3. Reportlinker Adds Greece Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2017
4. Reportlinker Adds Global Top 10 Pharmaceutical Companies: Industry, Financial and SWOT Analysis
5. Reportlinker Adds the Future of In Vitro and In Vivo Diagnostic Integration
6. Reportlinker Adds Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018
7. Reportlinker Adds Epidemiology: Major Abdominal Surgery - A key risk factor for deep vein thrombosis and pulmonary embolism
8. Reportlinker Adds The Antibacterials Market Outlook to 2016
9. Reportlinker Adds The Global Pharmaceutical Fine Chemicals Market Outlook to 2015
10. Reportlinker Adds The Drug-Eluting Stent Market Outlook to 2016
11. Reportlinker Adds The Infusion Pump Market Outlook to 2016
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... , May 23, 2016 Diplomat Pharmacy, Inc. (NYSE: ... Fellowship and Internship programs. The hands-on learning experience is ... The full-time, paid Fellowship and Internship ... . Fellows and interns are provided optional housing ... Flint at the Riverfront Residence Hall to ...
(Date:5/23/2016)... The World Health Organization (WHO) expanded the Intended ... adolescents aged 13 years, and above. Effective immediately, the PrePex ... and adolescent males in the 14 priority countries in Southern ... first male circumcision device to receive WHO Prequalification on 31 ... said: " The expanded use of PrePex ...
(Date:5/23/2016)... 2016 The global  reprocessed medical ... by 2022, according to a new study by Grand ... coupled with the lack of centralized support for waste ... the demand for reprocessed medical devices market. Additionally, the ... that of the original device is the high impact ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... ... and clinical practice of radiosurgery, is recognizing five medical residents and students for ... stereotactic body radiotherapy (SBRT). The awards will be presented at the 2016 SRS/SBRT ...
(Date:5/24/2016)... ... 24, 2016 , ... Bio-Logic Aqua® Research Water Life Science® ... a trainer for Ageless Grace ( http://www.agelessgrace.com ) to discuss healthier lifestyles, especially ... 2016. , Formerly a Northwestern University Literature Professor, Kinst gravitated to her career ...
(Date:5/24/2016)... ... May 24, 2016 , ... In light of recent ... of the potential of contaminated well water throughout the Houston area. , Heavy floodwaters ... well water that’s exposed to contaminants. Residents may not even be aware of the ...
(Date:5/24/2016)... ... 2016 , ... The Dream Builders Project, a 501(c)3 nonprofit organization based in ... in Tijuana, Mexico on Saturday, May 21st. The volunteers took the children out for ... More than 15 volunteers traveled from Los Angeles to Tijuana, Mexico for the day ...
(Date:5/24/2016)... Greenwich, Connecticut (PRWEB) , ... May 24, 2016 ... ... of Lyme and tick-borne disease research and education, today announced that it has ... and CEO of the Bonnie J. Addario Lung Cancer Foundation (ALCF) in San ...
Breaking Medicine News(10 mins):